Dissertation committee:
Ευάγγελος Φελέκουρας, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Σταμάτιος Θεοχάρης, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Εμμανουήλ Πικουλής, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ, Επιβλέπων
Ευστάθιος Αντωνίου, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Παύλος Πατάπης, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Ιωάννης Καραβοκυρός, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Κωνσταντίνος Νάστος, Επίκουρος Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Summary:
Background/Aim: We aimed to develop an animal model of colitis-associated colorectal cancer and determine the possible role of sCD40L in carcinogenesis by using the well-established azoxymethane/dextran sulfate sodium (AOM/DSS) protocol.
Material and methods:Twelve Wild type (WT) and twelve TLR4 Knock out (KO) female C57BL6 mice were divided into 4 experimental groups. Six female C57BL6 WT and six female C57BL6 TLR4 KO mice were treated with a single intraperitoneal dose (10 mg/kg of body weight) of AOM followed by three 7-day cycles of oral 2.5 % DSS, with each cycle interrupted by a 2-week rest period. The other two groups included 6 WT and 6 TLR4 KO mice that received only water and characterized as the control groups. The mice of each group were sacrificed at 84 days.
Results: All 6 animals of the WT group developed adenocarcinomas and from the TLR4 KO group 4 animals succumbed before the end of the procedures and the other 2 animals were protected from colorectal cancer. We measured the serum and pathologic tissue levels of sCD40L with quantitative sandwich enzyme-linked immunoassay (ELISA) and we aimed to check the hypothesis of a possible increased level of sCD40L in colitis associated cancer group.
Conclusion: Higher levels of sCD40L in serum were associated with colitis associated cancer.
